Free Trial
NASDAQ:VRTX

Vertex Pharmaceuticals Q2 2025 Earnings Report

Vertex Pharmaceuticals logo
$462.13 +5.26 (+1.15%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$466.26 +4.13 (+0.89%)
As of 08/1/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vertex Pharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
$4.24
Beat/Miss
N/A
One Year Ago EPS
N/A

Vertex Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.90 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vertex Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Monday, August 4, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Vertex Pharmaceuticals Earnings Headlines

3 Unstoppable Stocks to Buy in August
This Crypto Is Set to Explode in January
Free summit reveals where Bitcoin goes after $120k Don't miss this rare opportunity to learn directly from the experts who are driving this market…
How Will VRTX Stock React To Its Upcoming Earnings?
See More Vertex Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vertex Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vertex Pharmaceuticals and other key companies, straight to your email.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ:VRTX), a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

View Vertex Pharmaceuticals Profile

More Earnings Resources from MarketBeat